Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT04438083 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Start date: June 16, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.

NCT ID: NCT04416646 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

ZEBRA
Start date: February 27, 2019
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy of Cabozantinib in the treatment of patients with renal cell carcinoma.

NCT ID: NCT04405622 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Start date: May 30, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, single center, pilot trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.

NCT ID: NCT04401813 Active, not recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma

Start date: June 16, 2020
Phase: Phase 1
Study type: Interventional

An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma

NCT ID: NCT04398056 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to preliminarily evaluate the efficacy and safety of chemotherapy plus subsequent loco-regional radiotherapy combined with toripalimab for the de novo metastatic nasopharyngeal carcinoma.

NCT ID: NCT04394975 Active, not recruiting - Clinical trials for Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Start date: August 20, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, controlled, multicenter, phase III trial to compare the efficacy and safety of Toripalimab in combination with axitinib to sunitinib monotherapy as a first-line therapy for advanced RCC. Eligible patients will be randomized 1:1 to receive the combination therapy of Toripalimab and axitinib or sunitinib monotherapy.

NCT ID: NCT04389177 Active, not recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)

Start date: July 8, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin followed by Da Vinci robot radical surgery for locally advanced esophageal squamous cell carcinoma.

NCT ID: NCT04387682 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma of the Oral Cavity

Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients

Start date: March 22, 2017
Phase: N/A
Study type: Interventional

Oral squamous cell carcinoma (OSCC) has the highest annual increase in the rate of death among the top 10 leading cancers in Taiwan. This research aimed to explore whether increased anti-tumor immunity for OSCCs reduces the recurrence rate or improves survival. We first identified CD33+/CD11b+/HLA-DR-/low/CD14+/- as myeloid-derived suppressor cell (MDSC) surface markers by using flow cytometry to compare the MDSC frequency of OSCCs with blood samples from healthy donors (HDs). We then re-confirmed the suppression of T cell proliferation and function achieved by co-culturing with OSCC-educated MDSCs. We subsequently explore whether using particulate β-glucan as a food-grade supplement promotes the human immune system via subversion of immune modulatory MDSCs. Lastly, we correlated clinicopathological parameters with MDSCs and β-glucan administration to examine anti-tumor immunity, and to predict the therapeutic effect and prognosis in OSCC patients..

NCT ID: NCT04387500 Active, not recruiting - Clinical trials for Carcinoma, Renal Cell

Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of Sintilimab injection combined with Inlyta in fumarate hydratase-deficient renal cell carcinoma.

NCT ID: NCT04386746 Active, not recruiting - Bladder Cancer Clinical Trials

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

GEMDOCE
Start date: July 29, 2020
Phase: Phase 2
Study type: Interventional

A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-naïve patients with non-muscle invasive bladder cancer (NMIBC).